This is a single-site, randomised, double-blind, placebo-controlled, parallel, phase IIb
clinical trial. The primary objective of the SCOPE-BD study is to investigate the efficacy
and safety of IV Scopolamine, compared to placebo, in reducing severity of depression in
individuals with bipolar disorder who are experiencing a depressive episode of at least
moderate severity
Phase:
Phase 2
Details
Lead Sponsor:
Dr. Brian Hallahan
Collaborators:
HRB Clinical Research Facility Galway, Ireland National University of Ireland, Galway, Ireland Stanley Medical Research Institute University College Hospital Galway